Hemozoin Formation as a Target for Antimalarial Drug Design
Abstract
Malaria is the most significant of parasitic diseases accounting for at least one million deaths and over 100 million clinical cases each year in endemic tropical areas of the world. The main thrust of our proposed research is to optimize a tricyclic antimalarial agent for safety and efficacy. Selected tricyclics that have been prepared by us are able to inhibit growth of multidrug resistant strains of Plasmodium falciparum by 50% (IC50) at concentrations well below 1 nanomolar. These same compounds are without cytotoxicity toward human bone marrow progenitors until the concentration is increased more than 10,000-fold. We are currently evaluating these optimized tricyclics in a mouse model of malaria in order to assess toxicity and efficacy.
Document Details
- Document Type
- Technical Report
- Publication Date
- Feb 01, 2005
- Accession Number
- ADA442977
Entities
People
- Michael K. Riscoe